Request Appointment
8900 N Kendall DriveMiami, FL 33176
Overview of Dr. Mukherjee
Dr. Sarbajit Mukherjee is an oncologist in Miami, FL and is affiliated with multiple hospitals in the area, including Baptist Hospital of Miami and Roswell Park Comprehensive Cancer Center. He received his medical degree from NRS Medical College Calcutta and has been in practice 12 years. He is one of 100 doctors at Roswell Park Comprehensive Cancer Center and one of 54 doctors at Baptist Hospital of Miami who specialize in Oncology. He also speaks multiple languages, including Bengali and Hindi. He has more than 70 publications and over 500 citings.
Education & Training
University of OklahomaMS, Clinical and Translational Science, 2016 - 2018- University of OklahomaFellowship, 2015 - 2018
Saint Joseph HospitalResidency, Internal Medicine, 2012 - 2015
NRS Medical College CalcuttaClass of 2010
Certifications & Licensure
FL State Medical License 2025 - 2027
NY State Medical License 2018 - 2027
OK State Medical License 2015 - 2019
IL State Medical License 2012 - 2015
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Gold Humanism Honor Society GHHS, 2018
- Member, Occult Primary Panel National Comprehensive Cancer Network, 2018
- Board of Directors Esophageal Cancer Action Network, 2018
- Join now to see all
Clinical Trials
- Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer Start of enrollment: 2015 May 13
- Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) Start of enrollment: 2019 Jul 22
Roles: Contact, Sub-Investigator
- Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma Start of enrollment: 2023 Mar 07
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: A Phase II Study.Sarbajit Mukherjee, Yu Fujiwara, Christos Fountzilas, Harsha Pattnaik, Sarah Chatley
Cancer Medicine. 2025-04-01 - CLO25-098: Impact of Bone Metastasis on Survival in Gastric and Gastroesophageal Junction Tumors.Muhammad Awidi, Muntaser Al Zyoud, Osama M Younis, Sarbajit Mukherjee
Journal of the National Comprehensive Cancer Network. 2025-03-28 - Camrelizumab combined with neoadjuvant docetaxel, oxaliplatin, and S1 as induction therapy for locally advanced esophageal squamous cell cancer: a real-world single-ce...Guanghui Xu, Shushang Liu, Shu Wang, Jiyang Zheng, Yuhao Wang
Journal of Thoracic Disease. 2025-01-24
Journal Articles
- Woodchuck VEGF (wVEGF) characteristics: Model for angiogenesis and human hepatocellular carcinoma directed therapies.Huang H, Salavaggione O, Rivera L, Mukherjee S, Brekken R, Tennant B, Iyer R, Adjei A., Arch Biochem Biophys, 11/12/2018
Abstracts/Posters
- Can DNA Methylation Patterns be used as Predictive Biomarkers for Chemotherapy Response in Osteosarcoma?Mukherjee S, Jeffries M, Rivas A, Malik R, Ibrahimi S, Fung K, White J, Meyer W, Vesely S, Barkauskas D, Hall D, Cherry M., J Clin Oncol 36, 2018 (suppl; abstr 11525), 6/1/2018
- Efficacy of PD-1/PD-L1 Therapy: do proton pump inhibitors affect the outcome?Mukherjee S, Khalid B, Ibrahimi S, Morton J, Roman D, Zhao D, Aljumaily R., J Clin Oncol 36, 2018 (suppl 5S; abstr 208), 1/2018
- Effect of Body Mass Index and Albumin level on Outcomes of Patients Receiving Anti PD-1/PD-L1 TherapyIbrahimi S, Mukherjee S, Roman D, King C, Machiorlatti M, Aljumaily R., J Clin Oncol 36, 2018 (suppl 5S; abstr 213), 1/2018
- Join now to see all
Lectures
- Phase II study of trifluridine/tipiracil (FTD/TPI) and oxaliplatin as induction chemotherapy (IC) in resectable esophageal and gastroesophageal junction adenocarcinoma...ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
- On the Shoulders of Giants: Historical Approaches to Immunotherapy in Solid TumorsASCO annual meeting, Chicago, IL - 6/2017
- NANETS Regional NET Education: Multidisciplinary Management of NET CancersNorth American Neuroendocrine Tumor Society Regional meeting, Oklahoma City, OK - 11/2017
Authored Content
- Conducting Research During Your Oncology Fellowship: Obstacles and Opportunities6/28/2016
- Burnout Among Oncology Fellows: A Personal Perspective2/23/2016
Press Mentions
FTD/TPI plus Oxaliplatin Well-Tolerated but Not Broadly Effective as Treatment for Esophageal CancerApril 18th, 2023- Combo carboplatin/paclitaxel Dubbed New Standard of Care for Anal CancerJune 26th, 2020
- Sensitivity to Chemotherapy May Guide Treatment of Patients with Stomach CancerJanuary 21st, 2022
- Join now to see all
Professional Memberships
- American Society of Clinical OncologyMember
- American Association for Cancer ResearchMember
- American College of GastroenterologyMember
- American Society of HematologyMember
- Member
Other Languages
- Bengali, Hindi
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
